PDF(Pubmed)
Abstract：
Sjögren\'s syndrome (SS) is a systemic autoimmune pathology manifested mainly by a dry syndrome, intense asthenia and arthromyalgia. Systemic manifestations may also occur. Since 2019, immunosuppressant agents (IS) or biotherapies are recommended only for patients with systemic involvement. However, before 2019, in some cases, paucisymptomatic patients had been treated with IS/biotherapies, often off-label. Objective: We propose to evaluate the benefit and safety of using IS/biotherapy in patients with SS without systemic involvement. Methods: We retrospectively collected the clinical records of all patients with SS diagnosed according to ACR/EULAR diagnostic criteria followed up between January 1980 and October 2023 at Grenoble University Hospital (France). Results: Eighty-three patients were included: 64 with an initially non-systemic form. Of these patients with an initially non-systemic form, 24 were treated with IS/biotherapy. None of them developed secondary systematization, whereas 11 out of 40 patients in the untreated group did (p < 0.05). On the other hand, IS/biotherapy did not appear to improve dry syndrome. There were no serious adverse events. Conclusion: Early introduction of an IS/biotherapy treatment appears to provide a benefit for the patient without side effects.
摘要：
干燥综合征(SS)是一种以干燥综合征为主要表现的全身性自身免疫病理学,强烈的无力和关节肌痛。也可能出现系统性表现。自2019年以来，免疫抑制剂（IS）或生物疗法仅推荐用于全身受累的患者。然而,在2019年之前，在某些情况下，无症状的患者接受了IS/生物疗法治疗，通常是标签外的。目的：我们建议评估在无全身受累的SS患者中使用IS/生物疗法的益处和安全性。方法：我们回顾性收集了1980年1月至2023年10月在格勒诺布尔大学医院（法国）根据ACR/EULAR诊断标准诊断的所有SS患者的临床记录。结果：包括83例患者：64例最初为非全身形式。在这些最初为非全身形式的患者中，24例采用IS/生物疗法治疗。他们都没有发展二级系统化，而未经治疗组的40例患者中有11例（p<0.05）。另一方面,IS/生物疗法似乎不能改善干燥综合征。无严重不良事件发生。结论：早期引入IS/生物疗法治疗似乎为患者提供了益处，而没有副作用。
